bullish
HK Inno. N (195940 KS): Flagship Drug K-CAB Is Set to Become a Global Blockbuster Drug
443 Views23 May 2022 15:24
SUMMARY
- HK inno.N (195940 KS)'s K-CAB induces faster onset of action and can control gastric pH for a longer period than the existing treatments in acid-related disorders.
- K-CAB is expected to start global expansion in 2022. The drug obtained marketing approval in Philippines. It is already approved in China and is under clinical trial in the U.S.
- HK inno has entered into marketing alliances with several Southeast Asian and Latin American countries. The company aims to export the drug to 100 countries globally by 2028.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- HK Inno.N (195940 KS): 2024 Will See Robust Profit Growth On Growing Momentum of Key Drug23 Apr 2024
- HK Inno.N (195940 KS): 2Q23 Result Shows Strong Sequential Improvement; K-CAB Continues to Fly High03 Aug 2023
- HK Inno.N (INNO KS): On a Solid Growth Path with Blockbuster New Drug K-CAB19 Nov 2021
- HK Inno.N Post-Listing Immediate Float Analysis05 Aug 2021
x